JP2009541311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541311A5 JP2009541311A5 JP2009516446A JP2009516446A JP2009541311A5 JP 2009541311 A5 JP2009541311 A5 JP 2009541311A5 JP 2009516446 A JP2009516446 A JP 2009516446A JP 2009516446 A JP2009516446 A JP 2009516446A JP 2009541311 A5 JP2009541311 A5 JP 2009541311A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- isoindol
- phenyl
- amine
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 111
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 30
- 125000002877 alkyl aryl group Chemical group 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 21
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 12
- -1 alkenyl R 6 Chemical compound 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 7
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 6
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 230000003902 lesion Effects 0.000 claims 4
- LAQKOENYJDDTDY-UHFFFAOYSA-N 4-[3-amino-1-(4-hydroxyphenyl)isoindol-1-yl]phenol Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 LAQKOENYJDDTDY-UHFFFAOYSA-N 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- RXPHIWHATFBINA-UHFFFAOYSA-N 2-[3-amino-1-(4-hydroxyphenyl)isoindol-1-yl]phenol Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C(=CC=CC=1)O)C1=CC=C(O)C=C1 RXPHIWHATFBINA-UHFFFAOYSA-N 0.000 claims 2
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- KTVJPEWAPJPEOK-UHFFFAOYSA-N [3-[3-amino-1-(4-fluoro-3-pyrimidin-5-ylphenyl)isoindol-1-yl]phenyl] trifluoromethanesulfonate Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C(F)=CC=1)C=1C=NC=NC=1)C1=CC=CC(OS(=O)(=O)C(F)(F)F)=C1 KTVJPEWAPJPEOK-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 1
- RSWYTHKZAKEODI-UHFFFAOYSA-N 3,3-dimethylisoindol-1-amine Chemical compound C1=CC=C2C(C)(C)N=C(N)C2=C1 RSWYTHKZAKEODI-UHFFFAOYSA-N 0.000 claims 1
- FYQHSDGQCJETLW-UHFFFAOYSA-N 3,3-diphenylisoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FYQHSDGQCJETLW-UHFFFAOYSA-N 0.000 claims 1
- YFRVXHOJYFHAOP-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C2OCOC2=CC=1)C1=CC=CC(Br)=C1 YFRVXHOJYFHAOP-UHFFFAOYSA-N 0.000 claims 1
- YSHQEJDYWRDFNV-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC=CC=C2C(N)=NC1(C=1C=C2OCOC2=CC=1)C(C=1)=CC=CC=1C1=CN=CN=C1 YSHQEJDYWRDFNV-UHFFFAOYSA-N 0.000 claims 1
- PQRUSXIAEQXMOU-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-3-[3-(2-fluoropyridin-3-yl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC=CC=C2C(N)=NC1(C=1C=C2OCOC2=CC=1)C(C=1)=CC=CC=1C1=CC=CN=C1F PQRUSXIAEQXMOU-UHFFFAOYSA-N 0.000 claims 1
- HRNPAIOJTACERQ-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-3-[3-(3-methoxyphenyl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=C3OCOC3=CC=2)=C1 HRNPAIOJTACERQ-UHFFFAOYSA-N 0.000 claims 1
- VZDJIRZZYSFVRR-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-3-[3-(5-methoxypyridin-3-yl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CN=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=C3OCOC3=CC=2)=C1 VZDJIRZZYSFVRR-UHFFFAOYSA-N 0.000 claims 1
- KROAJEYJMROWNY-UHFFFAOYSA-N 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(3-pyridin-3-ylphenyl)isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C2OCCOC2=CC=1)C(C=1)=CC=CC=1C1=CC=CN=C1 KROAJEYJMROWNY-UHFFFAOYSA-N 0.000 claims 1
- KEKAVQSDOJVSNU-UHFFFAOYSA-N 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C2OCCOC2=CC=1)C(C=1)=CC=CC=1C1=CN=CN=C1 KEKAVQSDOJVSNU-UHFFFAOYSA-N 0.000 claims 1
- XLVJMWWGXURWKV-UHFFFAOYSA-N 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[3-(2-fluoropyridin-3-yl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC=CC=C2C(N)=NC1(C=1C=C2OCCOC2=CC=1)C(C=1)=CC=CC=1C1=CC=CN=C1F XLVJMWWGXURWKV-UHFFFAOYSA-N 0.000 claims 1
- HGLAOFZAFIFUKA-UHFFFAOYSA-N 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[3-(3-methoxyphenyl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=C3OCCOC3=CC=2)=C1 HGLAOFZAFIFUKA-UHFFFAOYSA-N 0.000 claims 1
- MXVJZGAFZLJLQZ-UHFFFAOYSA-N 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[3-(5-methoxypyridin-3-yl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CN=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=C3OCCOC3=CC=2)=C1 MXVJZGAFZLJLQZ-UHFFFAOYSA-N 0.000 claims 1
- USZVXCYBGOQIKE-UHFFFAOYSA-N 3-(2-chloropyridin-4-yl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(Cl)N=CC=1)C(C=1)=CC=CC=1C1=CN=CN=C1 USZVXCYBGOQIKE-UHFFFAOYSA-N 0.000 claims 1
- VOFJGSZKPNRYLS-UHFFFAOYSA-N 3-(2-chloropyridin-4-yl)-3-[3-(2-fluoropyridin-3-yl)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C(=NC=CC=1)F)C1=CC=NC(Cl)=C1 VOFJGSZKPNRYLS-UHFFFAOYSA-N 0.000 claims 1
- SRJWFQRFHSLIHN-UHFFFAOYSA-N 3-(2-ethylpyridin-4-yl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C1=NC(CC)=CC(C2(C3=CC=CC=C3C(N)=N2)C=2C=C(C=CC=2)C=2C=NC=NC=2)=C1 SRJWFQRFHSLIHN-UHFFFAOYSA-N 0.000 claims 1
- QXZLSUXNFCVKSB-UHFFFAOYSA-N 3-(2-ethylpyridin-4-yl)-3-[3-(2-fluoropyridin-3-yl)phenyl]isoindol-1-amine Chemical compound C1=NC(CC)=CC(C2(C3=CC=CC=C3C(N)=N2)C=2C=C(C=CC=2)C=2C(=NC=CC=2)F)=C1 QXZLSUXNFCVKSB-UHFFFAOYSA-N 0.000 claims 1
- FJKNWPNCHKXVKK-UHFFFAOYSA-N 3-(2-fluoropyridin-4-yl)-3-[3-(2-fluoropyridin-3-yl)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C(=NC=CC=1)F)C1=CC=NC(F)=C1 FJKNWPNCHKXVKK-UHFFFAOYSA-N 0.000 claims 1
- AQWJKONBZLFXLD-UHFFFAOYSA-N 3-(2-methoxypyrimidin-5-yl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C1=NC(OC)=NC=C1C1(C=2C=C(C=CC=2)C=2C=NC=NC=2)C2=CC=CC=C2C(N)=N1 AQWJKONBZLFXLD-UHFFFAOYSA-N 0.000 claims 1
- BSJUWHOXOHIPGJ-UHFFFAOYSA-N 3-(2-propan-2-ylpyridin-4-yl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C1=NC(C(C)C)=CC(C2(C3=CC=CC=C3C(N)=N2)C=2C=C(C=CC=2)C=2C=NC=NC=2)=C1 BSJUWHOXOHIPGJ-UHFFFAOYSA-N 0.000 claims 1
- LJUZMVAHVKHGST-UHFFFAOYSA-N 3-(3-bromophenyl)-3-(4-methoxyphenyl)isoindol-1-amine Chemical compound C1=CC(OC)=CC=C1C1(C=2C=C(Br)C=CC=2)C2=CC=CC=C2C(N)=N1 LJUZMVAHVKHGST-UHFFFAOYSA-N 0.000 claims 1
- JSLVKTXNNUWZNM-UHFFFAOYSA-N 3-(3-fluoropyridin-4-yl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C(=CN=CC=1)F)C(C=1)=CC=CC=1C1=CN=CN=C1 JSLVKTXNNUWZNM-UHFFFAOYSA-N 0.000 claims 1
- PZYOMIWKDHGKSK-UHFFFAOYSA-N 3-(3-fluoropyridin-4-yl)-3-(4-fluoro-3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C(=CN=CC=1)F)C(C=1)=CC=C(F)C=1C1=CN=CN=C1 PZYOMIWKDHGKSK-UHFFFAOYSA-N 0.000 claims 1
- HOUJQAJPWSQDKH-UHFFFAOYSA-N 3-(3-fluoropyridin-4-yl)-3-[3-(2-fluoropyridin-3-yl)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C(=CN=CC=1)F)C(C=1)=CC=CC=1C1=CC=CN=C1F HOUJQAJPWSQDKH-UHFFFAOYSA-N 0.000 claims 1
- SJYZHZUENNZOKO-UHFFFAOYSA-N 3-(3-fluoropyridin-4-yl)-3-[3-(5-fluoropyridin-3-yl)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C(=CN=CC=1)F)C(C=1)=CC=CC=1C1=CN=CC(F)=C1 SJYZHZUENNZOKO-UHFFFAOYSA-N 0.000 claims 1
- LJHBNAAXZYVNAM-UHFFFAOYSA-N 3-(3-pyrimidin-5-ylphenyl)-3-[4-(trifluoromethoxy)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=NC=1)C1=CC=C(OC(F)(F)F)C=C1 LJHBNAAXZYVNAM-UHFFFAOYSA-N 0.000 claims 1
- RRIIPJUEPHJBNE-UHFFFAOYSA-N 3-(3-pyrimidin-5-ylphenyl)-3-[4-(trifluoromethyl)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=NC=1)C1=CC=C(C(F)(F)F)C=C1 RRIIPJUEPHJBNE-UHFFFAOYSA-N 0.000 claims 1
- ZYLDGJNRPVVNPD-UHFFFAOYSA-N 3-(3-pyrimidin-5-ylphenyl)-3-[6-(trifluoromethyl)pyridin-3-yl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=NC=1)C1=CC=C(C(F)(F)F)N=C1 ZYLDGJNRPVVNPD-UHFFFAOYSA-N 0.000 claims 1
- MSERYTUPLPTPDE-UHFFFAOYSA-N 3-(4-fluoro-3-pyrimidin-5-ylphenyl)-3-(4-methoxy-3-methylphenyl)isoindol-1-amine Chemical compound C1=C(C)C(OC)=CC=C1C1(C=2C=C(C(F)=CC=2)C=2C=NC=NC=2)C2=CC=CC=C2C(N)=N1 MSERYTUPLPTPDE-UHFFFAOYSA-N 0.000 claims 1
- GGFAIDPBYPUUNF-UHFFFAOYSA-N 3-(4-fluoro-3-pyrimidin-5-ylphenyl)-3-pyridin-4-ylisoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C(F)=CC=1)C=1C=NC=NC=1)C1=CC=NC=C1 GGFAIDPBYPUUNF-UHFFFAOYSA-N 0.000 claims 1
- TXRDWFIBWSXSBA-UHFFFAOYSA-N 3-(4-methoxy-3-methylphenyl)-3-(3-pyridin-3-ylphenyl)isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(C)C(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=NC=CC=2)C2=CC=CC=C2C(N)=N1 TXRDWFIBWSXSBA-UHFFFAOYSA-N 0.000 claims 1
- SNPJMUOGKNZXET-UHFFFAOYSA-N 3-(4-methoxy-3-methylphenyl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(C)C(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=NC=NC=2)C2=CC=CC=C2C(N)=N1 SNPJMUOGKNZXET-UHFFFAOYSA-N 0.000 claims 1
- MBCXQRNZTXKTKR-UHFFFAOYSA-N 3-(4-methoxy-3-methylphenyl)-3-[3-(3-methoxyphenyl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=C(C)C(OC)=CC=2)=C1 MBCXQRNZTXKTKR-UHFFFAOYSA-N 0.000 claims 1
- LROAOFBLCCRMGM-UHFFFAOYSA-N 3-(4-methoxy-3-methylphenyl)-3-[3-(5-methoxypyridin-3-yl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CN=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=C(C)C(OC)=CC=2)=C1 LROAOFBLCCRMGM-UHFFFAOYSA-N 0.000 claims 1
- MKYWJTMYZCYVJX-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-(3-pyridin-3-ylphenyl)isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=NC=CC=2)C2=CC=CC=C2C(N)=N1 MKYWJTMYZCYVJX-UHFFFAOYSA-N 0.000 claims 1
- IOHWCZWSDVRWJX-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=NC=NC=2)C2=CC=CC=C2C(N)=N1 IOHWCZWSDVRWJX-UHFFFAOYSA-N 0.000 claims 1
- GDOBIUCVRRCMFC-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-[3-(3-methoxyphenyl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=C(OC)C=CC=2)C2=CC=CC=C2C(N)=N1 GDOBIUCVRRCMFC-UHFFFAOYSA-N 0.000 claims 1
- QLEQZKQBZIKYEV-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-[3-(5-methoxypyridin-3-yl)phenyl]isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=C(OC)C=NC=2)C2=CC=CC=C2C(N)=N1 QLEQZKQBZIKYEV-UHFFFAOYSA-N 0.000 claims 1
- RMAISUWIHRUGBW-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-[3-(5-methylfuran-2-yl)phenyl]isoindol-1-amine Chemical compound C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2OC(C)=CC=2)C2=CC=CC=C2C(N)=N1 RMAISUWIHRUGBW-UHFFFAOYSA-N 0.000 claims 1
- FFJATXOBCVGDHP-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-[3-[1-(2-methylpropyl)pyrazol-4-yl]phenyl]isoindol-1-amine Chemical compound C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C2=CN(CC(C)C)N=C2)C2=CC=CC=C2C(N)=N1 FFJATXOBCVGDHP-UHFFFAOYSA-N 0.000 claims 1
- NBDIOATZZYXJOM-UHFFFAOYSA-N 3-(5-fluoropyridin-3-yl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(F)C=NC=1)C(C=1)=CC=CC=1C1=CN=CN=C1 NBDIOATZZYXJOM-UHFFFAOYSA-N 0.000 claims 1
- HYXOWQSRITZXBL-UHFFFAOYSA-N 3-(5-fluoropyridin-3-yl)-3-[3-(2-fluoropyridin-3-yl)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(F)C=NC=1)C(C=1)=CC=CC=1C1=CC=CN=C1F HYXOWQSRITZXBL-UHFFFAOYSA-N 0.000 claims 1
- JEJCXMJBQASTNC-UHFFFAOYSA-N 3-[3-(2-fluoro-3-methoxyphenyl)phenyl]-3-(2-methoxypyrimidin-5-yl)isoindol-1-amine Chemical compound C1=NC(OC)=NC=C1C1(C=2C=C(C=CC=2)C=2C(=C(OC)C=CC=2)F)C2=CC=CC=C2C(N)=N1 JEJCXMJBQASTNC-UHFFFAOYSA-N 0.000 claims 1
- NHHIRTVYIYKDOS-UHFFFAOYSA-N 3-[3-(2-fluoro-3-methoxyphenyl)phenyl]-3-(3-fluoropyridin-4-yl)isoindol-1-amine Chemical compound COC1=CC=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C(=CN=CC=2)F)=C1F NHHIRTVYIYKDOS-UHFFFAOYSA-N 0.000 claims 1
- VKJAINYSPZGFJO-UHFFFAOYSA-N 3-[3-(2-fluoro-3-methoxyphenyl)phenyl]-3-pyridin-4-ylisoindol-1-amine Chemical compound COC1=CC=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=CN=CC=2)=C1F VKJAINYSPZGFJO-UHFFFAOYSA-N 0.000 claims 1
- RETGTHQYUNWAHX-UHFFFAOYSA-N 3-[3-(2-fluoro-5-methoxyphenyl)phenyl]-3-(3-fluoropyridin-4-yl)isoindol-1-amine Chemical compound COC1=CC=C(F)C(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C(=CN=CC=2)F)=C1 RETGTHQYUNWAHX-UHFFFAOYSA-N 0.000 claims 1
- JEGZOSORVFTJMV-UHFFFAOYSA-N 3-[3-(2-fluoro-5-methoxyphenyl)phenyl]-3-pyridin-4-ylisoindol-1-amine Chemical compound COC1=CC=C(F)C(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=CN=CC=2)=C1 JEGZOSORVFTJMV-UHFFFAOYSA-N 0.000 claims 1
- NKSILXQELSBYMB-UHFFFAOYSA-N 3-[3-(2-fluoropyridin-3-yl)phenyl]-3-(2-methoxypyridin-4-yl)isoindol-1-amine Chemical compound C1=NC(OC)=CC(C2(C3=CC=CC=C3C(N)=N2)C=2C=C(C=CC=2)C=2C(=NC=CC=2)F)=C1 NKSILXQELSBYMB-UHFFFAOYSA-N 0.000 claims 1
- UUSDJWZJKUREMM-UHFFFAOYSA-N 3-[3-(2-fluoropyridin-3-yl)phenyl]-3-(2-methoxypyrimidin-5-yl)isoindol-1-amine Chemical compound C1=NC(OC)=NC=C1C1(C=2C=C(C=CC=2)C=2C(=NC=CC=2)F)C2=CC=CC=C2C(N)=N1 UUSDJWZJKUREMM-UHFFFAOYSA-N 0.000 claims 1
- KIZUWEBHRSHYPU-UHFFFAOYSA-N 3-[3-(2-fluoropyridin-3-yl)phenyl]-3-(2-propan-2-ylpyridin-4-yl)isoindol-1-amine Chemical compound C1=NC(C(C)C)=CC(C2(C3=CC=CC=C3C(N)=N2)C=2C=C(C=CC=2)C=2C(=NC=CC=2)F)=C1 KIZUWEBHRSHYPU-UHFFFAOYSA-N 0.000 claims 1
- MLHMUENEDPHQIW-UHFFFAOYSA-N 3-[3-(2-fluoropyridin-3-yl)phenyl]-3-(4-methoxy-3-methylphenyl)isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(C)C(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C(=NC=CC=2)F)C2=CC=CC=C2C(N)=N1 MLHMUENEDPHQIW-UHFFFAOYSA-N 0.000 claims 1
- YFTSKYRBVZIRDF-UHFFFAOYSA-N 3-[3-(2-fluoropyridin-3-yl)phenyl]-3-(4-methoxyphenyl)isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C(=NC=CC=2)F)C2=CC=CC=C2C(N)=N1 YFTSKYRBVZIRDF-UHFFFAOYSA-N 0.000 claims 1
- HJVMFIHNKUTKTE-UHFFFAOYSA-N 3-[3-(2-fluoropyridin-3-yl)phenyl]-3-[4-(trifluoromethyl)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C(=NC=CC=1)F)C1=CC=C(C(F)(F)F)C=C1 HJVMFIHNKUTKTE-UHFFFAOYSA-N 0.000 claims 1
- PTCIWKKWVHRFHW-UHFFFAOYSA-N 3-[3-(2-fluoropyridin-3-yl)phenyl]-3-pyridin-4-ylisoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C(=NC=CC=1)F)C1=CC=NC=C1 PTCIWKKWVHRFHW-UHFFFAOYSA-N 0.000 claims 1
- CIDRLEIMPLDXQO-UHFFFAOYSA-N 3-[3-(3,5-dichlorophenyl)phenyl]-3-methylisoindol-1-amine;hydrochloride Chemical compound Cl.N1=C(N)C2=CC=CC=C2C1(C)C(C=1)=CC=CC=1C1=CC(Cl)=CC(Cl)=C1 CIDRLEIMPLDXQO-UHFFFAOYSA-N 0.000 claims 1
- BFHSMQZSRLOQTI-UHFFFAOYSA-N 3-[3-(3-amino-1-pyridin-4-ylisoindol-1-yl)phenyl]thiophene-2-carbaldehyde Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C1=C(SC=C1)C=O)C1=CC=NC=C1 BFHSMQZSRLOQTI-UHFFFAOYSA-N 0.000 claims 1
- ALDNAHUWWBRHNO-UHFFFAOYSA-N 3-[3-(3-chlorophenyl)phenyl]-3-methylisoindol-1-amine Chemical compound N1C(=N)C2=CC=CC=C2C1(C)C(C=1)=CC=CC=1C1=CC=CC(Cl)=C1 ALDNAHUWWBRHNO-UHFFFAOYSA-N 0.000 claims 1
- WCSKTLFQBJLKJT-UHFFFAOYSA-N 3-[3-(3-methoxyphenyl)phenyl]-3-methylisoindol-1-amine Chemical compound COC1=CC=CC(C=2C=C(C=CC=2)C2(C)C3=CC=CC=C3C(=N)N2)=C1 WCSKTLFQBJLKJT-UHFFFAOYSA-N 0.000 claims 1
- JUKOGXLVBBEBQA-UHFFFAOYSA-N 3-[3-(3-methoxyphenyl)phenyl]-3-pyridin-4-ylisoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=CN=CC=2)=C1 JUKOGXLVBBEBQA-UHFFFAOYSA-N 0.000 claims 1
- QQJUCVADWJXCSY-UHFFFAOYSA-N 3-[3-(3-methyl-2,3-dihydro-1h-isoindol-1-yl)phenyl]benzonitrile Chemical compound C12=CC=CC=C2C(C)NC1C(C=1)=CC=CC=1C1=CC=CC(C#N)=C1 QQJUCVADWJXCSY-UHFFFAOYSA-N 0.000 claims 1
- SKGVVQXEXZIEHI-UHFFFAOYSA-N 3-[3-(5-fluoropyridin-3-yl)phenyl]-3-[4-(trifluoromethoxy)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=C(F)C=NC=1)C1=CC=C(OC(F)(F)F)C=C1 SKGVVQXEXZIEHI-UHFFFAOYSA-N 0.000 claims 1
- UFXWEQDWXOAJIW-UHFFFAOYSA-N 3-[3-(5-fluoropyridin-3-yl)phenyl]-3-[4-(trifluoromethyl)phenyl]isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=C(F)C=NC=1)C1=CC=C(C(F)(F)F)C=C1 UFXWEQDWXOAJIW-UHFFFAOYSA-N 0.000 claims 1
- DRJVPYVKKPMDIR-UHFFFAOYSA-N 3-[3-(5-fluoropyridin-3-yl)phenyl]-3-pyridin-4-ylisoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=C(F)C=NC=1)C1=CC=NC=C1 DRJVPYVKKPMDIR-UHFFFAOYSA-N 0.000 claims 1
- QAKXQJHCDUDOQO-UHFFFAOYSA-N 3-[3-(5-methoxypyridin-3-yl)phenyl]-3-pyridin-4-ylisoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CN=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=CN=CC=2)=C1 QAKXQJHCDUDOQO-UHFFFAOYSA-N 0.000 claims 1
- XIFDYTNQUWAWNB-UHFFFAOYSA-N 3-[3-[1-(2-methylpropyl)pyrazol-4-yl]phenyl]-3-pyridin-4-ylisoindol-1-amine Chemical compound C1=NN(CC(C)C)C=C1C1=CC=CC(C2(C3=CC=CC=C3C(N)=N2)C=2C=CN=CC=2)=C1 XIFDYTNQUWAWNB-UHFFFAOYSA-N 0.000 claims 1
- BPXXEGHVWKYATP-UHFFFAOYSA-N 3-[3-[3-amino-1-(4-methoxyphenyl)isoindol-1-yl]phenyl]thiophene-2-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C2=C(SC=C2)C=O)C2=CC=CC=C2C(N)=N1 BPXXEGHVWKYATP-UHFFFAOYSA-N 0.000 claims 1
- QKRORMCMVMJWEP-UHFFFAOYSA-N 3-[4-fluoro-3-(2-fluoro-3-methoxyphenyl)phenyl]-3-(3-fluoropyridin-4-yl)isoindol-1-amine Chemical compound COC1=CC=CC(C=2C(=CC=C(C=2)C2(C3=CC=CC=C3C(N)=N2)C=2C(=CN=CC=2)F)F)=C1F QKRORMCMVMJWEP-UHFFFAOYSA-N 0.000 claims 1
- ATNOALNMPLKAIU-UHFFFAOYSA-N 3-[4-fluoro-3-(2-fluoropyridin-3-yl)phenyl]-3-(3-fluoropyridin-4-yl)isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C(=CN=CC=1)F)C(C=1)=CC=C(F)C=1C1=CC=CN=C1F ATNOALNMPLKAIU-UHFFFAOYSA-N 0.000 claims 1
- ZUAXXROTZBSKHM-UHFFFAOYSA-N 3-[4-fluoro-3-(2-fluoropyridin-3-yl)phenyl]-3-pyridin-4-ylisoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C(F)=CC=1)C=1C(=NC=CC=1)F)C1=CC=NC=C1 ZUAXXROTZBSKHM-UHFFFAOYSA-N 0.000 claims 1
- DZQCCINKSULBHS-UHFFFAOYSA-N 3-[4-fluoro-3-(5-fluoropyridin-3-yl)phenyl]-3-pyridin-4-ylisoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C(F)=CC=1)C=1C=C(F)C=NC=1)C1=CC=NC=C1 DZQCCINKSULBHS-UHFFFAOYSA-N 0.000 claims 1
- VXGRXODOHHHSFX-UHFFFAOYSA-N 3-amino-1-(1h-benzimidazol-2-yl)isoindole-1-carbonitrile Chemical compound C12=CC=CC=C2C(N)=NC1(C#N)C1=NC2=CC=CC=C2N1 VXGRXODOHHHSFX-UHFFFAOYSA-N 0.000 claims 1
- NYIANBGHFDKPOM-UHFFFAOYSA-N 3-amino-1-cyano-n-phenylisoindole-1-carboxamide Chemical compound C12=CC=CC=C2C(N)=NC1(C#N)C(=O)NC1=CC=CC=C1 NYIANBGHFDKPOM-UHFFFAOYSA-N 0.000 claims 1
- NQTZOXMJAFUJMD-UHFFFAOYSA-N 3-methyl-3-(3-pyridin-3-ylphenyl)isoindol-1-amine Chemical compound N1C(=N)C2=CC=CC=C2C1(C)C(C=1)=CC=CC=1C1=CC=CN=C1 NQTZOXMJAFUJMD-UHFFFAOYSA-N 0.000 claims 1
- DSTFDMSWHBZXPS-UHFFFAOYSA-N 3-methyl-3-phenylisoindol-1-amine Chemical compound N1C(=N)C2=CC=CC=C2C1(C)C1=CC=CC=C1 DSTFDMSWHBZXPS-UHFFFAOYSA-N 0.000 claims 1
- ZYXCFLDAYHAAAR-UHFFFAOYSA-N 3-methyl-3h-isoindol-1-amine Chemical compound C1=CC=C2C(C)N=C(N)C2=C1 ZYXCFLDAYHAAAR-UHFFFAOYSA-N 0.000 claims 1
- YKXKGPLMYVVUDT-UHFFFAOYSA-N 3-phenyl-3h-isoindol-1-amine Chemical compound C12=CC=CC=C2C(N)=NC1C1=CC=CC=C1 YKXKGPLMYVVUDT-UHFFFAOYSA-N 0.000 claims 1
- RZNCMYXAADNFLB-UHFFFAOYSA-N 3-pyridin-4-yl-3-(3-pyridin-3-ylphenyl)isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=CC=1)C1=CC=NC=C1 RZNCMYXAADNFLB-UHFFFAOYSA-N 0.000 claims 1
- RUJFNISIWQVPLN-UHFFFAOYSA-N 3-pyridin-4-yl-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=NC=1)C1=CC=NC=C1 RUJFNISIWQVPLN-UHFFFAOYSA-N 0.000 claims 1
- CUVALDHWVAAROZ-UHFFFAOYSA-N 4-[3-amino-1-(3-bromophenyl)isoindol-1-yl]benzonitrile Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(Br)C=CC=1)C1=CC=C(C#N)C=C1 CUVALDHWVAAROZ-UHFFFAOYSA-N 0.000 claims 1
- RKAZILWLWWIORU-UHFFFAOYSA-N 4-[3-amino-1-(3-pyrimidin-5-ylphenyl)isoindol-1-yl]benzonitrile Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=NC=1)C1=CC=C(C#N)C=C1 RKAZILWLWWIORU-UHFFFAOYSA-N 0.000 claims 1
- JGUHEQYTTIJUJK-UHFFFAOYSA-N 4-[3-amino-1-(4-hydroxy-3,5-dimethylphenyl)isoindol-1-yl]-2,6-dimethylphenol Chemical compound CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(N)=N2)C=2C=C(C)C(O)=C(C)C=2)=C1 JGUHEQYTTIJUJK-UHFFFAOYSA-N 0.000 claims 1
- OPNSCJWHJWVYTM-UHFFFAOYSA-N 4-[3-amino-1-(4-methoxyphenyl)isoindol-1-yl]-2-(3-methoxyphenyl)phenol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C(O)=CC=2)C=2C=C(OC)C=CC=2)C2=CC=CC=C2C(N)=N1 OPNSCJWHJWVYTM-UHFFFAOYSA-N 0.000 claims 1
- DPQXPEOLJIRZGE-UHFFFAOYSA-N 4-[3-amino-1-(4-methoxyphenyl)isoindol-1-yl]-2-pyridin-3-ylphenol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C(O)=CC=2)C=2C=NC=CC=2)C2=CC=CC=C2C(N)=N1 DPQXPEOLJIRZGE-UHFFFAOYSA-N 0.000 claims 1
- JFPLXCZOHUUFBT-UHFFFAOYSA-N 4-[3-amino-1-(4-methoxyphenyl)isoindol-1-yl]-2-pyrimidin-5-ylphenol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C(O)=CC=2)C=2C=NC=NC=2)C2=CC=CC=C2C(N)=N1 JFPLXCZOHUUFBT-UHFFFAOYSA-N 0.000 claims 1
- YHGVNGZOMYDXCF-UHFFFAOYSA-N 4-[3-amino-1-[3-(2-fluoropyridin-3-yl)phenyl]isoindol-1-yl]benzonitrile Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C(=NC=CC=1)F)C1=CC=C(C#N)C=C1 YHGVNGZOMYDXCF-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- RUVUPFARVUNSDR-UHFFFAOYSA-N 5-[3-[3-amino-1-(3-fluoropyridin-4-yl)isoindol-1-yl]phenyl]pyridine-3-carbonitrile Chemical compound C12=CC=CC=C2C(N)=NC1(C=1C(=CN=CC=1)F)C(C=1)=CC=CC=1C1=CN=CC(C#N)=C1 RUVUPFARVUNSDR-UHFFFAOYSA-N 0.000 claims 1
- VQEFHCMYLLDVIB-UHFFFAOYSA-N 5-chloro-3-pyridin-4-yl-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C12=CC(Cl)=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=NC=1)C1=CC=NC=C1 VQEFHCMYLLDVIB-UHFFFAOYSA-N 0.000 claims 1
- BZDDRLVYUUKKIW-UHFFFAOYSA-N 5-fluoro-3-(4-methoxyphenyl)-3-(3-pyridin-3-ylphenyl)isoindol-1-amine Chemical compound C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=NC=CC=2)C2=CC(F)=CC=C2C(N)=N1 BZDDRLVYUUKKIW-UHFFFAOYSA-N 0.000 claims 1
- QZKCUZLROIGMOS-UHFFFAOYSA-N 5-fluoro-3-(4-methoxyphenyl)-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=NC=NC=2)C2=CC(F)=CC=C2C(N)=N1 QZKCUZLROIGMOS-UHFFFAOYSA-N 0.000 claims 1
- AJQCLXNXTDWIPA-UHFFFAOYSA-N 5-fluoro-3-(4-methoxyphenyl)-3-[3-(3-methoxyphenyl)phenyl]isoindol-1-amine Chemical compound C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=C(OC)C=CC=2)C2=CC(F)=CC=C2C(N)=N1 AJQCLXNXTDWIPA-UHFFFAOYSA-N 0.000 claims 1
- QFKSZEAFTQSJDV-UHFFFAOYSA-N 5-fluoro-3-(4-methoxyphenyl)-3-[3-(5-methoxypyridin-3-yl)phenyl]isoindol-1-amine Chemical compound C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=C(OC)C=NC=2)C2=CC(F)=CC=C2C(N)=N1 QFKSZEAFTQSJDV-UHFFFAOYSA-N 0.000 claims 1
- ZFHOWIHCEQLHCF-UHFFFAOYSA-N 5-fluoro-3-[3-(2-fluoropyridin-3-yl)phenyl]-3-pyridin-4-ylisoindol-1-amine Chemical compound C12=CC(F)=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C(=NC=CC=1)F)C1=CC=NC=C1 ZFHOWIHCEQLHCF-UHFFFAOYSA-N 0.000 claims 1
- WTGLPGYDRWCHNT-UHFFFAOYSA-N 5-fluoro-3-[3-(5-methoxypyridin-3-yl)phenyl]-3-pyridin-4-ylisoindol-1-amine Chemical compound COC1=CN=CC(C=2C=C(C=CC=2)C2(C3=CC(F)=CC=C3C(N)=N2)C=2C=CN=CC=2)=C1 WTGLPGYDRWCHNT-UHFFFAOYSA-N 0.000 claims 1
- XTSAZQMJLSIBNL-UHFFFAOYSA-N 5-fluoro-3-pyridin-4-yl-3-(3-pyridin-3-ylphenyl)isoindol-1-amine Chemical compound C12=CC(F)=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=CC=1)C1=CC=NC=C1 XTSAZQMJLSIBNL-UHFFFAOYSA-N 0.000 claims 1
- COXOKDOOYGRMNE-UHFFFAOYSA-N 5-fluoro-3-pyridin-4-yl-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound C12=CC(F)=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=NC=1)C1=CC=NC=C1 COXOKDOOYGRMNE-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- IDQJDESLNNQYMH-UHFFFAOYSA-N [3-[3-[3-amino-1-(1,3-benzodioxol-5-yl)isoindol-1-yl]phenyl]-5-methoxyphenyl] methanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC(OS(C)(=O)=O)=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=C3OCOC3=CC=2)=C1 IDQJDESLNNQYMH-UHFFFAOYSA-N 0.000 claims 1
- PLKDXPYFYAWJED-UHFFFAOYSA-N [3-[3-[3-amino-1-(4-methoxy-3-methylphenyl)isoindol-1-yl]phenyl]-5-methoxyphenyl] methanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC(OS(C)(=O)=O)=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=C(C)C(OC)=CC=2)=C1 PLKDXPYFYAWJED-UHFFFAOYSA-N 0.000 claims 1
- PNFVQCDSLLSMOG-UHFFFAOYSA-N [3-[3-[3-amino-1-(4-methoxyphenyl)isoindol-1-yl]phenyl]-5-methoxyphenyl] methanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=C(OS(C)(=O)=O)C=C(OC)C=2)C2=CC=CC=C2C(N)=N1 PNFVQCDSLLSMOG-UHFFFAOYSA-N 0.000 claims 1
- ZNJSHSINBDEQKB-UHFFFAOYSA-N [4-[3-amino-1-(3-bromophenyl)isoindol-1-yl]phenyl] methanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OS(=O)(=O)C)=CC=C1C1(C=2C=C(Br)C=CC=2)C2=CC=CC=C2C(N)=N1 ZNJSHSINBDEQKB-UHFFFAOYSA-N 0.000 claims 1
- HRLQVKZRSQKIBW-UHFFFAOYSA-N [4-[3-amino-1-(3-pyrimidin-5-ylphenyl)isoindol-1-yl]phenyl] methanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OS(=O)(=O)C)=CC=C1C1(C=2C=C(C=CC=2)C=2C=NC=NC=2)C2=CC=CC=C2C(N)=N1 HRLQVKZRSQKIBW-UHFFFAOYSA-N 0.000 claims 1
- ODBYTPFKZXXSML-UHFFFAOYSA-N [4-[3-amino-1-(4-methoxyphenyl)isoindol-1-yl]-2-(3-methoxyphenyl)phenyl] trifluoromethanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1C1(C=2C=C(C(OS(=O)(=O)C(F)(F)F)=CC=2)C=2C=C(OC)C=CC=2)C2=CC=CC=C2C(N)=N1 ODBYTPFKZXXSML-UHFFFAOYSA-N 0.000 claims 1
- RKTKGQSNQAGRTQ-UHFFFAOYSA-N [4-[3-amino-1-[3-(2-fluoropyridin-3-yl)phenyl]isoindol-1-yl]phenyl] methanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OS(=O)(=O)C)=CC=C1C1(C=2C=C(C=CC=2)C=2C(=NC=CC=2)F)C2=CC=CC=C2C(N)=N1 RKTKGQSNQAGRTQ-UHFFFAOYSA-N 0.000 claims 1
- XWVDCYLXEAWZCU-UHFFFAOYSA-N [4-[3-amino-1-[3-(3-methoxy-5-methylsulfonyloxyphenyl)phenyl]isoindol-1-yl]phenyl] methanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC(OS(C)(=O)=O)=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=CC(OS(C)(=O)=O)=CC=2)=C1 XWVDCYLXEAWZCU-UHFFFAOYSA-N 0.000 claims 1
- ZGMDQLGLYBMLKT-UHFFFAOYSA-N [4-[3-amino-1-[3-(3-methoxyphenyl)phenyl]isoindol-1-yl]phenyl] methanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=CC(OS(C)(=O)=O)=CC=2)=C1 ZGMDQLGLYBMLKT-UHFFFAOYSA-N 0.000 claims 1
- VFJXZAFJRYDQCM-UHFFFAOYSA-N [4-[3-amino-1-[3-(5-methoxypyridin-3-yl)phenyl]isoindol-1-yl]phenyl] methanesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CN=CC(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C=2C=CC(OS(C)(=O)=O)=CC=2)=C1 VFJXZAFJRYDQCM-UHFFFAOYSA-N 0.000 claims 1
- WHXQTTHQYJFPEH-UHFFFAOYSA-N acetic acid;2-[3-(3-amino-1-cyclopropylisoindol-1-yl)phenyl]-4-methoxybenzonitrile Chemical compound CC(O)=O.COC1=CC=C(C#N)C(C=2C=C(C=CC=2)C2(C3=CC=CC=C3C(N)=N2)C2CC2)=C1 WHXQTTHQYJFPEH-UHFFFAOYSA-N 0.000 claims 1
- SXYVIPPBELUZSU-UHFFFAOYSA-N acetic acid;2-[3-(3-amino-1-methylisoindol-1-yl)phenyl]-4-methoxybenzonitrile Chemical compound CC(O)=O.COC1=CC=C(C#N)C(C=2C=C(C=CC=2)C2(C)C3=CC=CC=C3C(N)=N2)=C1 SXYVIPPBELUZSU-UHFFFAOYSA-N 0.000 claims 1
- RWSXLZHIIAOCND-UHFFFAOYSA-N acetic acid;3-[3-(2-fluoropyridin-3-yl)phenyl]-3-methylisoindol-1-amine Chemical compound CC(O)=O.N1=C(N)C2=CC=CC=C2C1(C)C(C=1)=CC=CC=1C1=CC=CN=C1F RWSXLZHIIAOCND-UHFFFAOYSA-N 0.000 claims 1
- YKKQOJCALFONIU-UHFFFAOYSA-N acetic acid;3-[3-(3,5-dichlorophenyl)phenyl]-3-(4-methoxyphenyl)isoindol-1-amine Chemical compound CC(O)=O.C1=CC(OC)=CC=C1C1(C=2C=C(C=CC=2)C=2C=C(Cl)C=C(Cl)C=2)C2=CC=CC=C2C(N)=N1 YKKQOJCALFONIU-UHFFFAOYSA-N 0.000 claims 1
- XBKNYNDDSNNHLN-UHFFFAOYSA-N acetic acid;3-[3-(5-fluoropyridin-3-yl)phenyl]-3-methylisoindol-1-amine Chemical compound CC(O)=O.N1=C(N)C2=CC=CC=C2C1(C)C(C=1)=CC=CC=1C1=CN=CC(F)=C1 XBKNYNDDSNNHLN-UHFFFAOYSA-N 0.000 claims 1
- IJFIEUYKOPJJBV-UHFFFAOYSA-N acetic acid;3-[3-(5-methylfuran-2-yl)phenyl]-3-pyridin-4-ylisoindol-1-amine Chemical compound CC(O)=O.O1C(C)=CC=C1C1=CC=CC(C2(C3=CC=CC=C3C(N)=N2)C=2C=CN=CC=2)=C1 IJFIEUYKOPJJBV-UHFFFAOYSA-N 0.000 claims 1
- HGBZLRDFRLWCEE-UHFFFAOYSA-N acetic acid;3-cyclopropyl-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound CC(O)=O.C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=NC=NC=1)C1CC1 HGBZLRDFRLWCEE-UHFFFAOYSA-N 0.000 claims 1
- RTXLJMPVHPGCQK-UHFFFAOYSA-N acetic acid;3-methyl-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound CC(O)=O.N1=C(N)C2=CC=CC=C2C1(C)C(C=1)=CC=CC=1C1=CN=CN=C1 RTXLJMPVHPGCQK-UHFFFAOYSA-N 0.000 claims 1
- NHEFJNWOSSJDEH-UHFFFAOYSA-N acetic acid;3-propan-2-yl-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine Chemical compound CC(O)=O.N1=C(N)C2=CC=CC=C2C1(C(C)C)C(C=1)=CC=CC=1C1=CN=CN=C1 NHEFJNWOSSJDEH-UHFFFAOYSA-N 0.000 claims 1
- MBMRYIYFZAGUFP-UHFFFAOYSA-N acetic acid;5-[3-(3-amino-1-pyridin-4-ylisoindol-1-yl)phenyl]pyridine-3-carbonitrile Chemical compound CC(O)=O.C12=CC=CC=C2C(N)=NC1(C=1C=C(C=CC=1)C=1C=C(C=NC=1)C#N)C1=CC=NC=C1 MBMRYIYFZAGUFP-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical group C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81580006P | 2006-06-22 | 2006-06-22 | |
| US81855706P | 2006-07-05 | 2006-07-05 | |
| US89124207P | 2007-02-23 | 2007-02-23 | |
| PCT/SE2007/000601 WO2007149033A1 (en) | 2006-06-22 | 2007-06-20 | Substituted isoindoles as bace inhibitors and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541311A JP2009541311A (ja) | 2009-11-26 |
| JP2009541311A5 true JP2009541311A5 (enExample) | 2010-09-16 |
Family
ID=38833680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009516446A Pending JP2009541311A (ja) | 2006-06-22 | 2007-06-20 | Ｂａｃｅインヒビターとしての置換イソインドール類及びそれらの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7855213B2 (enExample) |
| EP (1) | EP2035378A4 (enExample) |
| JP (1) | JP2009541311A (enExample) |
| KR (1) | KR20090031585A (enExample) |
| AR (1) | AR061564A1 (enExample) |
| AU (1) | AU2007261749B2 (enExample) |
| CA (1) | CA2656625A1 (enExample) |
| CL (1) | CL2007001830A1 (enExample) |
| EC (1) | ECSP088972A (enExample) |
| IL (1) | IL195670A0 (enExample) |
| MX (1) | MX2008015719A (enExample) |
| MY (1) | MY147390A (enExample) |
| NO (1) | NO20090246L (enExample) |
| NZ (1) | NZ574262A (enExample) |
| TW (1) | TW200815349A (enExample) |
| UY (1) | UY30426A1 (enExample) |
| WO (1) | WO2007149033A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2575340A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
| WO2006138264A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| US8722708B2 (en) | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
| CA2653650A1 (en) | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| TW200815349A (en) * | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| WO2009005471A1 (en) * | 2007-07-05 | 2009-01-08 | Astrazeneca Ab | Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
| WO2009005470A1 (en) * | 2007-07-05 | 2009-01-08 | Astrazeneca Ab | Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
| AU2009239536C1 (en) | 2008-04-22 | 2012-12-13 | Merck Sharp & Dohme Corp. | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use |
| MX2011002705A (es) | 2008-09-11 | 2011-09-09 | Amgen Inc | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso. |
| MX2011004680A (es) * | 2008-11-06 | 2011-05-25 | Astrazeneca Ab | Moduladores de beta amiloide. |
| WO2010056195A1 (en) * | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 575 |
| TW201020244A (en) * | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| WO2010056194A1 (en) * | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | 5h-pyrrolo [ 3, 4-b] pyridin derivatives and their use |
| WO2011002409A1 (en) * | 2009-07-02 | 2011-01-06 | Astrazeneca Ab | 5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase |
| EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| MX2012010658A (es) | 2010-03-15 | 2012-12-05 | Amgen Inc | Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa. |
| US8497264B2 (en) | 2010-03-15 | 2013-07-30 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| US20110281894A1 (en) * | 2010-05-12 | 2011-11-17 | Astrazeneca Ab | Hemifumarate salt |
| WO2012019056A1 (en) | 2010-08-05 | 2012-02-09 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
| US9284296B2 (en) | 2010-11-22 | 2016-03-15 | Aubergine Pharmaceuticals Llc | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
| US9346827B2 (en) | 2011-02-07 | 2016-05-24 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| RU2014111055A (ru) | 2011-08-22 | 2015-09-27 | Мерк Шарп И Доум Корп. | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение |
| WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| ES2745539T3 (es) | 2012-03-19 | 2020-03-02 | Buck Inst Res Aging | Inhibidores de BACE específicos de APP (ASBI) y uso de los mismos |
| WO2014062553A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2908825B1 (en) | 2012-10-17 | 2018-04-18 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| EP3653609B1 (en) | 2013-02-12 | 2024-04-03 | Buck Institute for Research on Aging | Hydantoins that modulate bace-mediated app processing |
| US20240383891A1 (en) * | 2023-05-16 | 2024-11-21 | Springworks Therapeutics, Inc. | Benzimidazole and related analogs for inhibiting yap/taz-tead |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| DE4419849A1 (de) | 1994-06-07 | 1995-12-14 | Hoechst Ag | Isoindolinpigmente |
| ES2135062T3 (es) | 1994-06-16 | 1999-10-16 | Pfizer | Pirazolo y pirrolopiridinas. |
| DE19516804A1 (de) * | 1995-05-08 | 1996-11-14 | Hoechst Ag | Isoindolinpigmente auf Basis von Aminochinoxalindionen |
| US5744346A (en) * | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| US6211235B1 (en) | 1996-11-22 | 2001-04-03 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting β-amyloid peptide release and/or its synthesis |
| GB9701684D0 (en) * | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
| WO1999011643A1 (en) | 1997-09-02 | 1999-03-11 | Du Pont Pharmaceuticals Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| ES2318902T3 (es) | 1998-09-24 | 2009-05-01 | PHARMACIA & UPJOHN COMPANY LLC | Secretasa en la enfermedad del alzheimer. |
| US6245884B1 (en) | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
| US6313268B1 (en) * | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
| WO2000047618A2 (en) | 1999-02-10 | 2000-08-17 | Elan Pharmaceuticals, Inc. | HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES |
| WO2000058479A1 (en) | 1999-03-26 | 2000-10-05 | Amgen Inc. | Beta secretase genes and polypeptides |
| US6376530B1 (en) * | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
| JP2003502342A (ja) | 1999-06-15 | 2003-01-21 | エラン ファーマスーティカルズ インコーポレイテッド | ベータ−セクレターゼのスタチン誘導テトラペプチド阻害剤 |
| EP1194449B1 (en) | 1999-06-28 | 2010-09-22 | Oklahoma Medical Research Foundation | Inhibitors of memapsin 2 and use thereof |
| DK1224297T3 (da) | 1999-09-23 | 2009-09-07 | Pharmacia & Upjohn Co Llc | Alzheimers sygdom -sekretase, APP-substrater derfor og anvendelser deraf |
| GB9924957D0 (en) | 1999-10-21 | 1999-12-22 | Smithkline Beecham Plc | Novel treatment |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| CA2410680A1 (en) | 2000-06-30 | 2002-01-10 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
| US6696488B2 (en) | 2000-08-11 | 2004-02-24 | The Brigham And Women's Hospital, Inc. | (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production |
| WO2002025276A1 (en) | 2000-09-22 | 2002-03-28 | Wyeth | Crystal structure of bace and uses thereof |
| JP2004149429A (ja) * | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2548388A1 (en) | 2003-12-15 | 2005-06-30 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| JP2007530696A (ja) | 2004-03-30 | 2007-11-01 | メルク エンド カムパニー インコーポレーテッド | アスパラギン酸プロテアーゼ阻害剤として有用な２−アミノチアゾール化合物 |
| AU2005244770A1 (en) * | 2004-04-26 | 2005-12-01 | Vanderbilt University | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity |
| WO2005123672A2 (en) | 2004-06-14 | 2005-12-29 | Takeda San Diego, Inc. | Kinase inhibitors |
| CA2579724A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
| CA2578600A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase |
| JPWO2006006520A1 (ja) | 2004-07-09 | 2008-04-24 | 株式会社ジェノファンクション | 新規創薬標的の探索方法 |
| JPWO2006006527A1 (ja) | 2004-07-12 | 2008-04-24 | 大日本印刷株式会社 | 電磁波シールドフィルタ |
| PT1789398E (pt) * | 2004-08-06 | 2010-10-21 | Janssen Pharmaceutica Nv | Derivados de 2-amino- quinazolina úteis como inibidores de β-secretase (bace) |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| BRPI0515532A (pt) | 2004-09-21 | 2008-07-29 | Athersys Inc | composto, composição farmacêutica, métodos de inibir a ligação de ligandos endógenos ao receptor de crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor de crt-2 e de preparar um composto, e, kit |
| CN101084198A (zh) | 2004-10-15 | 2007-12-05 | 阿斯利康(瑞典)有限公司 | 取代的氨基－嘧啶酮及其用途 |
| US20090221579A1 (en) | 2004-10-15 | 2009-09-03 | Jeffrey Scott Albert | Substituted Amino-Compounds and Uses Thereof |
| EP1831170A4 (en) | 2004-12-14 | 2009-10-14 | Astrazeneca Ab | SUBSTITUTED AMINOPYRIDINES AND THEIR USE |
| CN101103034A (zh) | 2005-01-14 | 2008-01-09 | 惠氏公司 | 抑制β-分泌酶的氨基-咪唑酮 |
| US20060223849A1 (en) | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| EP1896406A2 (en) | 2005-06-14 | 2008-03-12 | Shering Corporation | The preparation and use of compounds as protease inhibitors |
| WO2006138264A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| CA2609562A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Macrocyclic heterocyclic aspartyl protease inhibitors |
| US8722708B2 (en) | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
| US7759353B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment |
| ATE489370T1 (de) | 2005-06-14 | 2010-12-15 | Schering Corp | Herstellung und verwendung von verbindungen als aspartylproteasehemmer |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| BRPI0613578A2 (pt) | 2005-06-30 | 2012-01-17 | Wyeth Corp | composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica |
| CA2615656A1 (en) | 2005-07-18 | 2007-01-25 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| US7601751B2 (en) | 2005-09-01 | 2009-10-13 | Bristol-Myers Squibb Company | Indole acetic acid acyl guanidines as β-secretase inhibitors |
| ES2537898T3 (es) * | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| CN101296926A (zh) | 2005-10-27 | 2008-10-29 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
| CN101351460A (zh) | 2005-10-31 | 2009-01-21 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
| WO2007058580A1 (en) | 2005-11-15 | 2007-05-24 | Astrazeneca Ab | Novel 2-aminopyrimidinone derivatives and their use |
| CN101360721A (zh) | 2005-11-15 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基嘧啶酮衍生物或2-氨基吡啶酮衍生物及其用途 |
| JP2009515950A (ja) | 2005-11-15 | 2009-04-16 | アストラゼネカ・アクチエボラーグ | 新規な２−アミノピリミジン誘導体およびその使用 |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| CN101360716A (zh) | 2005-11-21 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途 |
| TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| AR058381A1 (es) | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
| JP2009532464A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ・アクチエボラーグ | ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用 |
| TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
| CA2653650A1 (en) | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| TW200815443A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds I |
| TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
| TW200808796A (en) | 2006-06-14 | 2008-02-16 | Astrazeneca Ab | New compounds III |
| TW200815449A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds II |
| TW200815349A (en) * | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| WO2008063114A1 (en) | 2006-11-20 | 2008-05-29 | Astrazeneca Ab | Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia |
| TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| WO2008076043A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5,5-diaryl-imidazol-4-ones |
| TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| WO2009005470A1 (en) | 2007-07-05 | 2009-01-08 | Astrazeneca Ab | Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
| WO2009005471A1 (en) | 2007-07-05 | 2009-01-08 | Astrazeneca Ab | Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
| WO2010056194A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | 5h-pyrrolo [ 3, 4-b] pyridin derivatives and their use |
| WO2010056195A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 575 |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
-
2007
- 2007-06-11 TW TW096121008A patent/TW200815349A/zh unknown
- 2007-06-13 US US11/762,487 patent/US7855213B2/en not_active Expired - Fee Related
- 2007-06-20 EP EP07748264A patent/EP2035378A4/en not_active Withdrawn
- 2007-06-20 KR KR1020097001336A patent/KR20090031585A/ko not_active Ceased
- 2007-06-20 MY MYPI20085213A patent/MY147390A/en unknown
- 2007-06-20 MX MX2008015719A patent/MX2008015719A/es active IP Right Grant
- 2007-06-20 AU AU2007261749A patent/AU2007261749B2/en not_active Ceased
- 2007-06-20 NZ NZ574262A patent/NZ574262A/en not_active IP Right Cessation
- 2007-06-20 JP JP2009516446A patent/JP2009541311A/ja active Pending
- 2007-06-20 CA CA002656625A patent/CA2656625A1/en not_active Abandoned
- 2007-06-20 WO PCT/SE2007/000601 patent/WO2007149033A1/en not_active Ceased
- 2007-06-21 CL CL200701830A patent/CL2007001830A1/es unknown
- 2007-06-21 AR ARP070102733A patent/AR061564A1/es not_active Application Discontinuation
- 2007-06-21 UY UY30426A patent/UY30426A1/es not_active Application Discontinuation
-
2008
- 2008-12-02 IL IL195670A patent/IL195670A0/en unknown
- 2008-12-12 EC EC2008008972A patent/ECSP088972A/es unknown
-
2009
- 2009-01-15 NO NO20090246A patent/NO20090246L/no not_active Application Discontinuation
-
2010
- 2010-11-11 US US12/944,145 patent/US20110059992A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2682665C (en) | Triazinone and diazinone derivatives useful as hsp90 inhibitors | |
| AU2015279377B2 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
| US8329736B2 (en) | Triazole compounds that modulate HSP90 activity | |
| JP5441691B2 (ja) | Ｈｓｐ９０活性を調節するトリアゾール化合物 | |
| AU2007267847B2 (en) | Triazole compounds that modulate Hsp90 activity | |
| ES2261476T3 (es) | Derivados de quinolina y quinazolina que inhiben la farnesil-tranferasa como inhibidores de farnesil-tranferasa. | |
| JP2011515462A5 (enExample) | ||
| JP2008513514A5 (enExample) | ||
| CA2796967A1 (en) | Heterocyclic derivatives as alk inhibitors | |
| WO2019025440A1 (en) | COMBINATION OF ATR KINASE INHIBITORS AND PD-1 / PD-L1 INHIBITORS | |
| TW200843740A (en) | Triazole compounds that modulate Hsp90 activity | |
| EP3585365B1 (en) | Combination of atr kinase inhibitors with parp inhibitors | |
| JP2006528147A5 (enExample) | ||
| CA2868323A1 (en) | Novel triazole compounds that modulate hsp90 activity | |
| WO2018153969A1 (en) | Combination of atr kinase inhibitors with radium-223 salt | |
| WO2018206547A1 (en) | Combination of bub1 and atr inhibitors | |
| JP2009501745A5 (enExample) | ||
| KR101457027B1 (ko) | 트리아진 유도체와 이들의 치료적 용도 | |
| JP2012522806A (ja) | 抗ウイルス処置のためのインドール誘導体および方法 | |
| JP2006522775A5 (enExample) | ||
| JP2006504714A5 (enExample) | ||
| JP2006508102A5 (enExample) | ||
| RU2008148901A (ru) | Замещенные изоиндолы в качестве ингибиторов васе и их применение | |
| WO2025040546A1 (en) | Pyrazole compounds as cullin ring ubiquitin ligase compounds | |
| TH93366A (th) | ไอโซอินโดลที่ถูกแทนที่เป็นสารยับยั้ง bace และการใช้สารเหล่านี้ |